The earnings miss and revenue contraction are negative signals for a pre-revenue biotech, but the ASGCT presentation on May 12 and upcoming IND/CTA filings could provide near-term catalysts. Watch for any updates on regulatory progress or partnership news that could offset the weak financials.
Price Chart
Executive Summary
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.24 by 16.7%, and revenue of $856K, down 41% YoY. The company reiterated cash runway into 2027 and highlighted pipeline progress (IND/CTA filings for Wilson disease and AATD in H1 2026), but the earnings miss and revenue decline signal near-term bearishness.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$0.28 vs consensus -$0.24 (16.7% miss)
- Q1 2026 revenue: $856K, down 41% from $1.454M YoY
- Cash, equivalents, investments: $149.2M as of March 31, 2026, providing runway into 2027
- Net loss: $49.1M vs $51.9M in Q1 2025 (improvement but above consensus expectations)
- Pipeline on track: IND/CTA for PM577 (Wilson) in H1 2026 and PM647 (AATD) mid-2026; BLA filing for PM359 (CGD) under FDA dialogue
Financial Impact
EPS miss of $0.04 (16.7%) and revenue decline of $598K (41% YoY)
Risk Factors
- Cash runway only into 2027 may require dilutive financing
- Clinical trial delays or regulatory setbacks for lead programs
- Further EPS misses could erode investor confidence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031719 |
| Document: prme-20260507.htm | 0001628280-26-031719 |
| Document: 0001628280-26-031719-index-headers.html | 0001628280-26-031719 |
| Document: 0001628280-26-031719-index.html | 0001628280-26-031719 |
| Document: 0001628280-26-031719.txt | 0001628280-26-031719 |
| 8-K Data (Synthetic) | 0001628280-26-031719 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | Press Release | $2.90 | awaiting T+60 | — | $3.67 (+26.55%) |
Aug 6, 2026 11w ago | 8-K | $2.95 | awaiting T+60 | — | $3.67 (+24.41%) |
Jul 8, 2026 15w ago | 8-K | $4.62 $3.06 | ▼ −33.87% | ▼ −36.19% | $3.67 (−20.56%) |
Jun 18, 2026 18w ago | Press Release | $3.23 $3.18 | ▼ −1.55% | ▼ −3.44% | $3.67 (+13.62%) |
May 7, 2026 24w ago | 8-K | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.67 (−17.82%) |
May 7, 2026 24w ago | Press Release | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.67 (−17.82%) |
Apr 16, 2026 27w ago | 8-K | $3.67 $3.52 | ▼ −4.22% | ▼ −11.27% | $3.67 (+0.00%) |
Mar 3, 2026 33w ago | Press Release | $4.23 $3.30 | ▼ −21.99% | ▼ −32.30% | $3.67 (−13.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers